The comparison of the effict of honey orabase and topical corticosteroid in the managment of recurrent minor aphthous ulceration

the comparison of efficacy of honey orabase 10 precent and topical corticosteroid in the managment of recurrent minor aphthous ulceration

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201201318883N1

Enrollment

104

Registered

2012-05-26

Start date

2012-04-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

oral minor aphthous. Recurrent oral aphthae

Interventions

Intervention 1: mucoadhesive topical honey with 10 percent,4 times a day on the wound for 5 day. Intervention 2: mucoadhesive topical corticosteroid,4 times a day on the wound for 5 day. Intervention

Treatment - Drugs

mucoadhesive topical honey with 10 percent,4 times a day on the wound for 5 day

mucoadhesive topical corticosteroid,4 times a day on the wound for 5 day

mucoadhesive topical without medicine,4 times a day on the wound for 5 day

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with 1 to 5 wounds that present in less than last 24 hours and are smaller than 5 millimeter; Pain in the region of ulcer without anesthesia or parasthesia; males and females between 18 and 65 years old. Exclusion criteria: Known history of serious drug hypersensitivities; pregnancy and lactation; History of having known systemic disease; Taking Non-steroidal anti-inflammatory drugs or oral antihistamines in 1 month before entering to the study; Taking systemic steroid or other immune-modulatory agents in 1 month before entering to the study; treatment of the ulcer with any medication before entering to the study; treatment with systemic antibiotics 2 weeks before entering to the study; aphthous ulcers adjacent tooth trauma from sharp edge, broken restorations, orthodontic appliances or partial denture.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Ulser size. Timepoint: at dey zero, one, two, seven after treatment. Method of measurement: photography of the wounds from the same distances and measuring the diameter of the wounds using the stereological software considering its zoom level will be surveyed.;Level of pain. Timepoint: at dey zero, one, two, seven after treatment. Method of measurement: pain that patients can express it with the VAS.	—

Measure

Time frame

Ulser size. Timepoint: at dey zero, one, two, seven after treatment. Method of measurement: photography of the wounds from the same distances and measuring the diameter of the wounds using the stereological software considering its zoom level will be surveyed.;Level of pain. Timepoint: at dey zero, one, two, seven after treatment. Method of measurement: pain that patients can express it with the VAS.

—

Secondary

Measure	Time frame
Effectiveness. Timepoint: at days zero, one, two,seven after treatment. Method of measurement: effectiveness index.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr.Mariye Honarmand

Zahedan University of Medical Sciences

honarmand56@yahoo.com00

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026